tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
Company AnnouncementsAstellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
5d ago
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
PremiumCompany Announcements
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
1M ago
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
PremiumRatings
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
2M ago
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment
PremiumCompany Announcements
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment
2M ago
Astellas Reports Strong Preliminary Sales for IZERVAY™ in Q1 FY2025
PremiumCompany Announcements
Astellas Reports Strong Preliminary Sales for IZERVAY™ in Q1 FY2025
3M ago
Astellas Pharma Continues Performance-linked Stock Schemes for Executives
PremiumCompany AnnouncementsAstellas Pharma Continues Performance-linked Stock Schemes for Executives
5M ago
Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
Premium
Company Announcements
Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
5M ago
Astellas Pharma Announces Changes to Board of Directors
Premium
Company Announcements
Astellas Pharma Announces Changes to Board of Directors
5M ago
Astellas Pharma Reports Record Revenue and Growth
PremiumCompany Announcements
Astellas Pharma Reports Record Revenue and Growth
6M ago
Astellas Pharma Reports Higher Than Expected Financial Results
PremiumCompany Announcements
Astellas Pharma Reports Higher Than Expected Financial Results
6M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
PremiumCompany Announcements
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
8M ago
Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
PremiumCompany AnnouncementsAstellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
9M ago
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
Premium
Company Announcements
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
9M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9M ago
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
PremiumCompany Announcements
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
9M ago
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
PremiumCompany Announcements
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
9M ago
Astellas Faces FDA Setback on IZERVAY Application
PremiumCompany Announcements
Astellas Faces FDA Setback on IZERVAY Application
11M ago
Astellas Pharma Faces Currency Losses in FY2024
PremiumCompany Announcements
Astellas Pharma Faces Currency Losses in FY2024
12M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12M ago
Astellas Pharma Withdraws EU Application for Key Drug
Premium
Company Announcements
Astellas Pharma Withdraws EU Application for Key Drug
12M ago
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
Premium
Company Announcements
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
12M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >